Aptalis Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aptalis Pharma Inc.
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
The era of follow-on medicinal chemistry has largely been eliminated by more comprehensive patent protection. Nowadays, investors trade on the differences in safety and efficacy for similar molecules.
Promising new clinical results presented at ESMO are likely to help several Chinese firms gain traction to take their new drug candidates into global markets, including the US.
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.
- Other Names / Subsidiaries
- Axcan Pharma, Inc.
- Eurand N.V.
- Mpex Pharmaceuticals, Inc.